Rebamipide

瑞巴派特

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameRebamipide
Drug Alias NamePramipide瑞贝派特Rebamipidum瑞吗派特Rebamipida +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin agonistsReceptor-type tyrosine-protein phosphatase zeta stimulantsMidkine stimulants
TargetsProstaglandinReceptor-type tyrosine-protein phosphatase zetaMidkine
Therapy Area/IndicationsDyspepsiaDry Eye SyndromesXerophthalmia +[15] 
Global Approved IndicationsStomach UlcerPeptic UlcerInflammatory Bowel Diseases +[4] 
Approved Indications in ChinaStomach Ulcer
Original Approved Country/TerritoryJapan
Original Approved Date1990/09/28
Country/TerritoryUnited StatesEgyptSouth Korea +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTokushima Workshop 2 Otsuka Pharmaceutical Co LtdOtsuka Holdings Co LtdCairo University +[4] 
Inactive CompaniesPt Otsuka IndonesiaOtsuka Pharmaceutical Development & Commercialization IncAddpharma Inc +[9] 
Active IndicationsOral UlcerBehcet SyndromeStomach Ulcer +[7] 
Inactive IndicationsDyspepsiaDry Eye SyndromesXerophthalmia +[8] 

Other Information

ATC CodeA02BX14
Related LinksWikipediaKEGG